Role of the PACAP––PAC₁––DISC1 and PACAP––PAC₁––stathmin1 systems in schizophrenia and bipolar disorder: novel treatment mechanisms?

Author： Katayama Taiichi Hattori Tsuyoshi Yamada Kohei Matsuzaki Shinsuke Tohyama Masaya

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.10, Iss.12, 2009-12, pp. : 1967-1978

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Regulation of pituitary adenylyl cyclase-activating polypeptide (PACAP, ADCYAP1: adenylyl cyclase-activating polypeptide 1) in the treatment of schizophrenia

By Matsuzaki Shinsuke Tohyama Masaya

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 9, 2008-09 ,pp. : 1097-1108

Informa Healthcare

Access to resources Recommend Favorite

Interaction of lipophilic VIP derivatives with recombinant VIP 1 /PACAP and VIP 2 /PACAP receptors

By Gourlet P. Rathe J. De Neef P. Cnudde J. Vandermeers-Piret M.-C. Waelbroeck M. Robberecht P.

European Journal of Pharmacology, Vol. 354, Iss. 1, 1998-07 ,pp. : 105-111

Elsevier

Access to resources Recommend Favorite

Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities

Current Medicinal Chemistry, Vol. 23, Iss. 3, 2016-01 ,pp. : 201-241

Bentham Science Publishers

Access to resources Recommend Favorite

Stathmin 1: a protein with many tasks. New biomarker and potential target in cancer

By Nemunaitis John

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 7, 2012-07 ,pp. : 631-634

Informa Healthcare

Access to resources Recommend Favorite

Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia

Current Neuropharmacology, Vol. 3, Iss. 1, 2005-01 ,pp. : 35-43

Bentham Science Publishers

Access to resources Recommend Favorite